التفاصيل البيبلوغرافية
| العنوان: |
Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 2). |
| المؤلفون: |
Qaseem, Amir, Yost, Jennifer, Abraham, George M., Andrews, Rebecca, Jokela, Janet A., Miller, Matthew C., Humphrey, Linda L., Obley, Adam J., Akl, Elie A., Dunn, Andrew, Forciea, Mary Ann, Haeme, Ray, Kansagara, Devan L., Lee, Rachael, Mackey, Katherine, Marcucci, Maura, Saini, Sameer D., Tschanz, CDR Mark P., Wilt, Timothy J., Carroll, Kate |
| المصدر: |
Annals of Internal Medicine; Oct2023, Vol. 176 Issue 10, p1396-1404, 11p, 1 Color Photograph, 1 Diagram, 4 Charts |
| مصطلحات موضوعية: |
COVID-19 treatment, SARS-CoV-2 Omicron variant, PHYSICIANS, MEDICAL sciences, HEALTH policy |
| مستخلص: |
The Population Health and Medical Science Committee of the American College of Physicians (ACP) updates the living, rapid practice points on the treatment of adults with COVID-19 in an outpatient setting. Practice points are based on a living, rapid review done by the ACP Center for Evidence Reviews at Cochrane Austria at the University for Continuing Education Krems. Description: Evidence for the use of outpatient treatments in adults with confirmed COVID-19 continues to evolve with new data. This is version 2 of the American College of Physicians (ACP) living, rapid practice points focusing on 22 outpatient treatments for COVID-19, specifically addressing the dominant SARS-CoV-2 Omicron variant. Methods: The Population Health and Medical Science Committee (formerly the Scientific Medical Policy Committee) developed this version of the living, rapid practice points on the basis of a living, rapid review done by the ACP Center for Evidence Reviews at Cochrane Austria at the University for Continuing Education Krems (Danube University Krems). This topic will be maintained as living and rapid by continually monitoring and assessing the impact of new evidence. Practice Point 1: Consider molnupiravir to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease. Practice Point 2: Consider nirmatrelvir–ritonavir combination therapy to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease. Practice Point 3: Do not use ivermectin to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting. Practice Point 4: Do not use sotrovimab to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting. [ABSTRACT FROM AUTHOR] |
|
Copyright of Annals of Internal Medicine is the property of American College of Physicians and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
